OrbiMed is a healthcare-focused investment firm based in New York City, managing approximately $19 billion in assets. The firm invests across the healthcare spectrum, from early-stage startups to large multinational companies, with a focus on biopharmaceuticals and medical technologies.
Online destinations
Where to find this organization online, grouped by who runs each page. A link here does not mean the organization controls it.
Pages the organization runs itself.
Third-party rankings
| Ranking | Edition | Position | Since last edition | Trust | What it measures |
|---|---|---|---|---|---|
 The top 100 venture investors in biotech | 2026 | #1 | No prior edition | A | Activity, Finance |
| Strebulaev-Jackson Venture Ranking: Top 50 Biotech VC Firms | 2026 | #2 | No prior edition | B | Performance |
 Leading longevity investors by deal count (Longevity Investors Conference) | 2025 | #10 | No prior edition | C | Activity |
| Strebulaev-Jackson Venture Ranking: Top 100 US VC Firms | 2026 | #27 | No prior edition | B | Performance |
OrbiMed is a global investment firm focused exclusively on the healthcare sector. Founded in 1989, originally as Mehta & Isaly, it was restructured and renamed OrbiMed Advisors in 1998. The firm manages approximately $20 billion across public and private company investments worldwide, employing a team of over 150 professionals with expertise in scientific, medical, and investment fields. OrbiMed's investment strategy encompasses a variety of healthcare sectors, including biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services, targeting investments across different stages from early-stage private companies to large multinational corporations.
OrbiMed invests in a variety of healthcare sectors, including biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. The firm targets investments across different stages, with a global investment strategy.
OrbiMed adds significant value to its portfolio companies through its extensive industry expertise, global network, and multi-strategy investment approach. The firm provides not only capital but also strategic guidance and support throughout the lifecycle of its investments, enabling companies to navigate challenges and seize growth opportunities.
OrbiMed invests in healthcare companies across various stages, from pre-seed to growth equity. The firm focuses on biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. They look for innovative solutions that address significant healthcare challenges and prefer founders with strong scientific backgrounds.
Founders can pitch to OrbiMed through their website. It is advisable to include a detailed business plan, market analysis, and information about the founding team in the pitch deck. A warm introduction can enhance the chances of getting noticed.
OrbiMed stands out due to its exclusive focus on healthcare and its multi-strategy investment approach. The firm manages a diverse portfolio that includes venture capital, public equity, and royalty/credit funds, allowing them to provide comprehensive support to their portfolio companies.
OrbiMed typically co-leads Series A, B, and C rounds with check sizes ranging from $10 million to $30 million, depending on the round size. They are not typically involved in pre-seed or seed investments.
OrbiMed has a strong follow-on investment strategy, enabled by its multi-vehicle structure that includes venture capital and royalty/credit funds. This allows them to support portfolio companies throughout their lifecycle.
OrbiMed has a global investment strategy, focusing primarily on the United States but also investing in companies worldwide. They have established a presence in various international markets to identify promising healthcare innovations.
From public sources
PitchBook's public OrbiMed preview lists Slate Medicines with deal date 2026-08-17.
Source: OrbiMed investment portfolio | PitchBookPitchBook's public OrbiMed preview lists Leal Therapeutics with deal date 2026-08-17.
Source: OrbiMed investment portfolio | PitchBookPitchBook's public OrbiMed preview lists Kincellis Advanced Therapies with deal date 2026-09-17.
Source: OrbiMed investment portfolio | PitchBookPitchBook's public OrbiMed preview lists Altis Labs with deal date 2026-09-17.
Source: OrbiMed investment portfolio | PitchBookOrbiMed lists Evan Caplan, M.D. as Partner.
Source: Leadership - OrbiMedOrbiMed lists Diyong Xu as Partner.
Source: Leadership - OrbiMedOrganizations that do similar work to OrbiMed.
InvestorHuman Capital is a multi-stage venture capital firm that partners with exceptional founders to build companies addressing critical industry challenges. They focus on assembling high-caliber teams and deploying capital to support these ventures.
InvestorDeerfield Management is a New York City-based investment management firm specializing in healthcare investments, managing over $15 billion in assets across more than 200 companies. The firm focuses on both public and private investments in sectors such as biotechnology, medical devices, and digital health.
InvestorEmpowering innovation through strategic investments.
InvestorEmpowering high-growth potential companies in Asia-Pacific.
Superscout Pro
Is this page right?Reviewed · How the research works